| Literature DB >> 1307347 |
J Morita1, M Yoshino, H Watari, I Yoshida, T Motohiro, F Yamashita, Y Okano, T Hashimoto.
Abstract
Wilson's disease is an autosomal recessive disorder characterized by an accumulation of a toxic amount of copper in the body. Triethylene tetramine dihydrochloride (trientine, 2HCl) is a new chelating agent that may be effective in the removal of excess copper but long-term efficacy has not yet been investigated. Here we report the use of trientine over more than 8 years in 2 patients with Wilson's disease who could not tolerate D-penicillamine. We found no significant side effect, except a decreased serum iron concentration without clinical symptoms of anemia. In annual examinations at a steady state, the serum copper levels remained below 20 micrograms/100 ml. The 24-hour urinary copper excretion was less than that found using D-penicillamine, while the basal copper excretion, after 5 days abstinence from trientine, was maintained below 100 micrograms/day. Both hepatic and neurological manifestations except bulbar symptoms were recovered without any initial deterioration.Entities:
Mesh:
Substances:
Year: 1992 PMID: 1307347 DOI: 10.1159/000457456
Source DB: PubMed Journal: Dev Pharmacol Ther ISSN: 0379-8305